GlassScriptPhysician profile
Bassam Choudhry
NPI 1477833028
$1,592.54
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $925 · 2021: $141 · 2022: $14.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,046.91 | 2019-2022 | |
| Astellas Pharma US INC | $165.48 | 2019 | |
| Glaxosmithkline, LLC. | $161.21 | 2019-2021 | |
| Roche Diagnostics Corporation | $50.00 | 2019 | |
| La Jolla Pharmaceutical Company | $35.77 | 2021 | |
| Grifols USA, LLC | $29.34 | 2021 | |
| Philips North America LLC | $25.95 | 2019 | |
| Shire North American Group INC | $16.66 | 2019 | |
| Allergan, INC. | $16.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.52 | 2019 | |
| Insmed, INC. | $16.24 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassam Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.